Foundation News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.

Filter results

5 Major Advances in Inflammatory Bowel Disease (IBD) Treatment

Breakthrough research from the 2020 Crohn’s & Colitis Congress®, a meeting to transform IBD care.

January 23, 2020

Crohn’s & Colitis Foundation Selected for FDA MyStudies App Project

NEW YORK, NY – The Crohn’s & Colitis Foundation announced today that it was selected as one of two patient organizations to participate in an U.S.

September 27, 2019

New Research Reveals High Cost of Care for Inflammatory Bowel Disease Patients in the United States

NEW YORK, NY – The cost of care for inflammatory bowel disease (IBD) in the United States has increased significantly over the past five years, according to the results of the Crohn’s & Colitis Foundation’s cost of care study.

May 21, 2019

Crohn's & Colitis Foundation Unveils New Five-Year Research Agenda

NEW YORK, NY – Today, the Crohn’s & Colitis Foundation released its new five-year research agenda to address unmet needs in the inflammatory bowel disease (IBD) research community and provide a roadmap for not only the Foundation but also the IBD research community at-large.

May 16, 2019

Leading Gastroenterology Organizations Announce Funding to Improve Vaccine Utilization and Preventive Health Maintenance

New York, New York – The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the Crohn’s & Colitis Foundation (Foundation), in partnership with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address vaccine utilizati

March 8, 2019

Crohn’s & Colitis Foundation Launches New Online Journal

New York, New York – The Crohn’s & Colitis Foundation is launching a new open access journal to engage, inform, and catalyze dialogue on state-of-the-art, comprehensive care for more than 3 million Americans living with inflammatory bowel diseases (IBD).

January 24, 2019

Predictimmune and the Crohn’s & Colitis Foundation Announce a Joint Study to Validate and Prove Efficacy of First Prognostic Test for IBD in the US Market

CAMBRIDGE, England—PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.

December 4, 2018

Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) Receives Funding

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.

May 17, 2018

The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis Services

Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.

April 17, 2018

Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel Diseases

The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.

April 17, 2018